This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VIVO Meridian Bioscience (VIVO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Meridian Bioscience Stock (NASDAQ:VIVO) Get Meridian Bioscience alerts:Sign Up Key Stats Today's Range$33.97▼$33.9750-Day Range$33.00▼$33.9752-Week Range$20.35▼$34.38VolumeN/AAverage Volume973,737 shsMarket Capitalization$1.50 billionP/E Ratio35.02Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH. Read More Receive VIVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIVO Stock News HeadlinesMeridian Bioscience Introduces New Enzyme Stabilization Services for Molecular DiagnosticsApril 24, 2025 | finance.yahoo.comMeridian Bioscience Inc (VIVO)April 10, 2025 | uk.investing.comShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.October 25 at 2:00 AM | Brownstone Research (Ad)Meridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to SustainabilityNovember 7, 2024 | finance.yahoo.comWill iQOO 13 launch at same price as iQOO 12? New leak provides major hintOctober 25, 2024 | msn.comMeridian Growth Legacy MERDXOctober 16, 2024 | morningstar.comMVivo V40 vs Realme GT 6T: How the two mid-range smartphones compareAugust 11, 2024 | msn.comMeridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic ManufacturersJuly 23, 2024 | finance.yahoo.comSee More Headlines VIVO Stock Analysis - Frequently Asked Questions How were Meridian Bioscience's earnings last quarter? Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its quarterly earnings data on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.21 by $0.03. The firm earned $76.20 million during the quarter, compared to the consensus estimate of $68.40 million. Meridian Bioscience had a trailing twelve-month return on equity of 16.74% and a net margin of 12.70%. Does Meridian Bioscience have any subsidiaries? Meridian Bioscience subsidiaries include Exalenz Bioscience. What other stocks do shareholders of Meridian Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Meridian Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Micron Technology (MU) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/12/2021Today10/25/2025Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:VIVO CIK794172 Webwww.meridianbioscience.com Phone(513) 271-3700Fax513-271-3762Employees702Year Founded1977Profitability EPS (Trailing Twelve Months)$0.97 Trailing P/E Ratio35.02 Forward P/E Ratio40.93 P/E GrowthN/ANet Income$42.46 million Net Margins12.70% Pretax Margin16.31% Return on Equity16.74% Return on Assets13.09% Debt Debt-to-Equity Ratio0.07 Current Ratio3.63 Quick Ratio2.46 Sales & Book Value Annual Sales$333.02 million Price / Sales4.49 Cash Flow$1.78 per share Price / Cash Flow19.13 Book Value$8.41 per share Price / Book4.04Miscellaneous Outstanding Shares44,010,000Free Float42,996,000Market Cap$1.50 billion OptionableOptionable Beta0.23 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:VIVO) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Meridian Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Meridian Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIVO Stock Alerts